Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genzyme Sales Of Myozyme Doubled In Fourth Quarter 2007

This article was originally published in The Pink Sheet Daily

Executive Summary

Enzyme replacement therapy for Pompe disease recorded $62 million in sales in the quarter, representing the most rapid growth of any of the firm’s lysosomal products.
Advertisement

Related Content

Pending Approvals Hold Major Implications For Myozyme Growth
Pending Approvals Hold Major Implications For Myozyme Growth
Icahn Leaves Pool, Genzyme Shareholder No More
Icahn Leaves Pool, Genzyme Shareholder No More
Genzyme, Isis Partner On Lipid Lowering Treatment Based On Antisense Technology
BioMarin, Genzyme Restructure Aldurazyme Joint Venture
Myozyme Is First FDA-Approved Inherited Muscle Disorder Therapy
Myozyme Is First FDA-Approved Inherited Muscle Disorder Therapy
Genzyme Predicts $5 Bil. In Annual Revenues By 2010 From Current Portfolio

Topics

Advertisement
UsernamePublicRestriction

Register

PS066847

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel